首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1093813

脉络膜新生血管的全球市场(2022年～2029年)

Global Choroidal Neovascularization Market - 2022-2029

出版日期: 2022年06月24日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告提供全球脉络膜新生血管市场相关调查分析，提供市场动态，产业分析，市场分析，竞争情形等系统性资讯。

简介
- 市场规模分析，及与前一年同期比较成长分析(%):各治疗类型
- 市场魅力指数:各治疗类型
光线动态疗法*
- 简介
- 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
- beruteporufin(Visudyne)
抗VEGF疗法
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)
- Aflibercept intravitreal (Eylea)
- Pegaptanib (Macugen)
- Brolucizumab intravitreal
其他

第10章全球脉络膜新生血管市场:各治疗药销售

简介
- 市场规模分析，及与前一年同期比较成长分析(%):各治疗药销售
- 市场魅力指数:各治疗药销售
治疗销售*
- 医院
- 其他
通路
- 医院药局
- 零售药局
- 线上药局
- 其他

第11章全球脉络膜新生血管市场:各地区

简介
市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年):各地区
市场魅力指数:各地区
北美
欧洲
南美
亚太地区
中东和非洲

第12章全球脉络膜新生血管市场-竞争情形

主要的开发与策略
企业占有率分析
产品的基准
值得注意的主要企业

第13章全球脉络膜新生血管市场-企业简介概要

Bayer AG*
- 企业概要
- 产品系列及说明
- 主要亮点
- 财务概要
Novartis AG
Bausch Health Companies Inc
Gilead Sciences Inc
F.Hoffmann-La Roche AG
MaaT Pharma
Pfizer Inc
Quark Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Suzuken Co.Ltd

第14章全球脉络膜新生血管市场-DataM

附录
关于本公司·服务
咨询方式

简介目录

Product Code: DMPH5468

Market Overview

The global choroidal neovascularization market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

New blood vessels that sprout right beneath the retina and obstruct vision are choroidal neovascular. The choroid is the area between the sclera and the retina where blood vessels form and cause choroidal neovascularization, responsible for oxygen and nutrient supply to the eye (CNV). The blockade between the choroid and the retina is broken by choroidal neovascularization, and the membrane in the retina leaks, causing visual loss. Choroidal neovascularization causes histoplasmosis, ocular damage, wet age-related macular degeneration, and myopic macular degeneration, among other serious eye illnesses. Because of the great elongation of their eyeball, myopic macular degeneration is most commonly encountered in elderly persons, resulting in vision loss. Idiopathic infections, choroidal tumors, and degeneration are the most common causes of choroidal neovascular disease.

Market Dynamics

The increasing prevalence of age-related macular degeneration (ARMD), pathologic myopia, ocular histoplasmosis, choroidal tears, angioid streaks, and inflammatory diseases of the retina choroid is propelling the market growth. Furthermore, the growing geriatric population, more vulnerable to serious health conditions, is a key factor driving the market growth.

Increase in prevalance of age-related macular degeneration (ARMD), pathologic myopia in the market is expected to drive the market growth

The market for choroidal neovascularization is being pushed by an increase in age-related macular degeneration (ARMD) and pathologic myopia. The estimated number of people with Age-Related Macular Degeneration will double by 2050, from 2.07 million to 5.44 million. The majority of cases will pursue to be dominated by white Americans. On the other hand, Hispanics will see the fastest rate of increase, with a nearly six-fold increase in the number of expected cases from 2010 to 2050.

A major risk factor for age-related macular degeneration is age. The likelihood of developing advanced age-related macular degeneration rises from 2% for individuals aged 50 to 59 to about 30% for those aged 75 and up. The prevalence of pathologic myopia ranged from 0.9 percent to 3.1 percent. In comparison, the prevalence of visual impairment due to pathologic myopia was reported to range from 0.1 percent to 0.5 percent (European studies) and 0.2 percent to 1.4 percent (American studies) (Asian studies). Choroidal neovascularization was shown to be prevalent in people with pathologic myopia, ranging from 5.2 percent to 11.3 percent, and was bilateral in about 15% of cases.

The growing geriatric population, more vulnerable to serious health conditions, is a key factor driving the market growth. According to WHO, by 2030, one in every six people on the planet will be 60 or older. At this point, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of 60 and up will have doubled (2.1 billion). The total number of eighty and up people is expected to triple between 2020 and 2050, reaching 426 million. Furthermore, the increasing use of combination drugs and the introduction of long-lasting anti-VEGF drugs are driving up demand for choroidal neovascularization treatments globally. Other factors, such as improved healthcare infrastructure and increased investments in research and development (R&D), are also contributing to the market's growth.This contributes to the growth of the global choroidal neovascularization .

High cost of treatment will hamper the market growth

Lack of awareness among people about various types of eye diseases, high treatment costs, lack of access to primary healthcare services in developing countries, lack of health insurance, and poor primary healthcare infrastructure are some of the vital factors restraining the growth of the global choroidal neovascularization market. In addition, rising healthcare costs in developing countries such as China and India are making healthcare facilities unaffordable for the aging populati COVID-19 Impact Analysis

As a result of the coronavirus disease spread, several countries' healthcare systems have become overburdened. As a result, doctors concentrate on patient selection, safe injection techniques, and adequate sterilization to reduce the danger of developing and transferring the disease. In non-emergency situations, they either reschedule and postpone follow-up sessions or provide remote monitoring options to patients with severe diseases using telehealth.

Segment Analysis

The malignant myopia degeneration segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Over the projection period, the malignant myopia degeneration segment is expected to increase. The rising number of operations, malignant myopia degeneration cases, and the rising geriatric population contribute to the segment's rise. Myopia is one of the key causes of visual impairment worldwide, and its prevalence has been increasing over the last few decades. By 2050, 49.8 percent of the world's population will have myopia, and 9.8 percent will have high myopia, posing a significant economic burden globally. Individuals with a high level of myopia are more likely to develop myopia-related blinding complications, the most common of which are malignant myopia degeneration, resulting in a progressive loss of visual acuity.

Furthermore, according to WHO, the number and proportion of people 60 aged and up are growing. In 2019, there were one billion people aged 60 and over. This figure is calculated to increase to 1.4 billion by 2030 and 2.1 billion by 2050, and the rise in the geriatric population is also one of the main key drivers to the segment's growth.

Geographical Analysis

North America region holds the largest market share of global choroidal neovascularization market

North America held the largest market share in 2019 and is expected to maintain this position throughout the forecast period attributed to the region's growing baby boomer population and rising incidences of choroidal diseases. Other factors contributing to the market's growth include the increasing use of combination drugs, and the introduction of long-lasting anti-VEGF drugs is driving up demand for CNV treatments globally. Other factors include improved healthcare infrastructure and increased investments in research and development ( R&D). The population of the US is aging. More than 46 million older adults aged 65 and older; by 2050, that number will increase to 90 million. The number of older adults is calculated to rise by nearly 18 million between 2020 and 2030 when the last of the baby boom cohorts reach the age of 75. This means that by 2030, one in every five Americans will be 75 or older. This factor also plays a prominent role. Furthermore, many key players in North America are a major factor driving market growth.

However, Asia-Pacific is assessed to grow the fastest during the forecast period, owing to increased healthcare spending and increased awareness about a different treatment option. Other factors that contribute to the market's growth include a large patient base of chronic diseases such as pathologic myopia and inflammatory diseases of retina and choroid, which contribute to the growth of the Asia-Pacific choroidal neovascularization market.

Competitive Landscape

The choroidal neovascularization market is highly competitive with the presence of local as well as global companies. Some of the key players contributing to the market's growth include Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann -La Roche AG,MaaT Pharma Novartis AG, Pfizer Inc, Quark Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Suzuken Co.Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the choroidal neovascularization market globally. For instance, in Oct 2021, Bausch + Lomb and Clearside Biomedical have announced that the FDA has approved XIPERETM (triamcinolone acetonide injectable suspension) for Suprachoroidal Use in the Treatment of Macular Edema Associated with Uveitis.

Bayer AG

Overview: The Bayer Group is a multinational corporation with core health care and agriculture competencies. Bayer HealthCare, a division of Bayer AG, is based in Leverkusen, Germany, and is one of the world's leading, innovative companies in the medical products and healthcare industries. The company combines the global operations of the divisions Animal Health, Consumer Care, Medical Care, and Pharmaceuticals. The goal of Bayer HealthCare is to discover, develop, manufacture, and market products that will improve human and animal health around the world.

Product Portfolio:

EYLEA: Eylea is the brand name for the medication aflibercept. It prevents abnormal blood vessels in the back of the eye from growing and leaking fluid. These blood vessels can leak and impair vision, resulting in wet AMD and diabetic eye disease. EYLEA is now approved to treat visual impairment caused by myopic choroidal neovascularization (myopic CNV). Myopic CNV is a retinal disease that frequently affects working-age people and is associated with high degrees of myopia (near-sightedness).

1. Global Choroidal Neovascularization Market Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Global Choroidal Neovascularization Market- Market Definition and Overview

3. Global Choroidal Neovascularization Market- Executive Summary

3.1. Market Snippet By Product Type
3.2. Market Snippet By Application
3.3. Market Snippet By Treatment Type
3.4. Market Snippet by Treatment Sales
3.5. Market Snippet by Region

4. Global Choroidal Neovascularization Market- Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising prevalence of age related macular degeneration
  - 4.1.1.2. Driver 2
- 4.1.2. Restraints:
  - 4.1.2.1. Lack of awareness among people about different types of eye diseases.
  - 4.1.2.2. Restraint 2
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Global Choroidal Neovascularization Market- Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis

6. Global Choroidal Neovascularization Market- COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. Global Choroidal Neovascularization Market- By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
- 7.1.2. Market Attractiveness Index, By Product Type Segment
7.2. Intravitreal*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Intravenous

8. Global Choroidal Neovascularization Market- By Application

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Malignant Myopia Degeneration*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Extreme Myopia
8.4. Age-Related Developments

9. Global Choroidal Neovascularization Market- By Treatment Type

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.1.2. Market Attractiveness Index, By Treatment Type Segment
9.2. Photodynamic Therapy*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 9.2.3. Verteporfin (Visudyne)
9.3. Anti-VEGF therapy
- 9.3.1. Ranibizumab (Lucentis)
- 9.3.2. Bevacizumab (Avastin)
- 9.3.3. Aflibercept intravitreal (Eylea)
- 9.3.4. Pegaptanib (Macugen)
- 9.3.5. Brolucizumab intravitreal
9.4. Others

10. Global Choroidal Neovascularization Market- By Treatment Sales

10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
- 10.1.2. Market Attractiveness Index, By Treatment Sales Segment
10.2. Treatment Sales*
- 10.2.2. Hospitals
- 10.2.3. Others
10.3. Distribution channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.3.4. Others

11. Global Choroidal Neovascularization Market- By Region

11.1. Introduction
11.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.3. Market Attractiveness Index, By Region
11.4. North America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
- 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. U.S.
  - 11.4.7.2. Canada
  - 11.4.7.3. Mexico
11.5. Europe
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
- 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. Germany
  - 11.5.7.2. U.K.
  - 11.5.7.3. France
  - 11.5.7.4. Italy
  - 11.5.7.5. Spain
  - 11.5.7.6. Rest of Europe
11.6. South America
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
- 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.6.7.1. Brazil
  - 11.6.7.2. Argentina
  - 11.6.7.3. Rest of South America
11.7. Asia Pacific
- 11.7.1. Introduction
- 11.7.2. Key Region-Specific Dynamics
- 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
- 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.7.7.1. China
  - 11.7.7.2. India
  - 11.7.7.3. Japan
  - 11.7.7.4. Australia
  - 11.7.7.5. Rest of Asia Pacific
11.8. Middle East and Africa
- 11.8.1. Introduction
- 11.8.2. Key Region-Specific Dynamics
- 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
- 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales

12. Global Choroidal Neovascularization Market- Competitive Landscape

12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. Key Companies to Watch

13. Global Choroidal Neovascularization Market- Company Profiles

13.1. Bayer AG*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Key Highlights
- 13.1.4. Financial Overview
13.2. Novartis AG
13.3. Bausch Health Companies Inc
13.4. Gilead Sciences Inc
13.5. F.Hoffmann -La Roche AG
13.6. MaaT Pharma
13.7. Pfizer Inc
13.8. Quark Pharmaceuticals Inc
13.9. Regeneron Pharmaceuticals Inc
13.10. Suzuken Co.Ltd

LIST NOT EXHAUSTIVE

14. Global Choroidal Neovascularization Market- DataM

14.1. Appendix
14.2. About Us and Services
14.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

脉络膜新生血管的全球市场(2022年～2029年)

Global Choroidal Neovascularization Market - 2022-2029

目录

第1章全球脉络膜新生血管市场调查手法和范围

第2章全球脉络膜新生血管市场-市场定义和概要

第3章全球脉络膜新生血管市场-摘要整理

第4章全球脉络膜新生血管市场-市场动态

第5章全球脉络膜新生血管市场-产业分析

第6章全球脉络膜新生血管市场上COVID-19分析

第7章全球脉络膜新生血管市场:各产品类型

第8章全球脉络膜新生血管市场:各应用领域

第9章全球脉络膜新生血管市场:各治疗类型